title: Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion.
abstract: Dickkopf-1 (DKK1) was known as a negative regulator of the Wnt signaling pathway, which played a crucial role in carcinogenesis. However, its function in human cancers remained elusive. In this study, we aimed to investigate the role of DKK1 in ovarian serous papillary adenocarcinoma (OSC) tumor progression and invasion. Quantitative real-time RT-PCR and Western blot analysis showed that the expression of DKK1 mRNA and protein in 32 OSC tissues were elevated as compared with those in 10 normal ovarian tissues (P = 0.005, P = 0.003, respectively). Immunohistochemical analysis in 178 clinical OSC samples showed that the expression of DKK1 was positively associated with FIGO stage (P = 0.016). Furthermore, the expression of DKK1 protein was positively associated with P-JNK1 protein expression in 178 OSC tissues. DKK1, P-JNK1 and the co-expression of DKK1 and P-JNK1 were all unfavorable prognosis factors for OSC patients (P < 0.0001). DKK1, alone or combined with P-JNK1, was an independent predictor for the 5 year survival (P = 0.015, P < 0.0001, respectively). DKK1 could promote OSC cells invasion and the growth of OSC nude mice xenograft. DKK1 in OSC cells could activate P-JNK1 expression and significantly promote formations of actin filaments and filopodia. Thus, DKK1, alone or combined with P-JNK1, was a novel prognostic predictor for OSC patients and contributed to the invasion of OSC.
authors: Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Heping District, Shenyang, Liaoning, China.
authors: Shizhuo
authors: S
authors: Wang
authors: Shulan
authors: S
authors: Zhang
references: Int J Biol Markers. 2009 Jul-Sep;24(3):165-70
references: 19787627
references: Br J Cancer. 2007 Oct 8;97(7):964-70
references: 17876334
references: Curr Biol. 2000 Dec 14-28;10(24):1611-4
references: 11137016
references: Nat Rev Cancer. 2003 May;3(5):362-74
references: 12724734
references: Mol Cell Biol. 2008 Apr;28(7):2368-79
references: 18212053
references: Cancer Res. 2004 Dec 1;64(23):8585-94
references: 15574765
references: Nature. 1998 Jan 22;391(6665):357-62
references: 9450748
references: J Hepatol. 2009 May;50(5):948-57
references: 19303159
references: Cancer Res. 2001 Nov 15;61(22):8085-8
references: 11719432
references: Gene. 1999 Oct 1;238(2):301-13
references: 10570958
references: Br J Cancer. 2007 Feb 26;96(4):646-53
references: 17245340
references: Eur J Gynaecol Oncol. 1999;20(3):237-9
references: 10410898
references: Oncogene. 2004 Nov 4;23(52):8520-6
references: 15378020
references: Cancer Res. 2007 Sep 1;67(17):7983-6
references: 17804706
references: Science. 2000 Mar 3;287(5458):1606-9
references: 10733430
references: Minerva Med. 2009 Oct;100(5):385-400
references: 19910891
references: J Cell Biochem. 2006 Mar 1;97(4):661-72
references: 16447163
references: Gynecol Oncol. 2010 Jul;118(1):88-92
references: 20439111
references: Trends Cell Biol. 2004 Feb;14(2):94-101
references: 15102441
references: Lab Invest. 2003 Mar;83(3):429-34
references: 12649343
references: Cancer Res. 2007 Mar 15;67(6):2517-25
references: 17363569
references: Clin Cancer Res. 2010 Jan 1;16(1):184-94
references: 20028751
references: Curr Opin Genet Dev. 2007 Feb;17(1):45-51
references: 17208432
references: Annu Rev Cell Dev Biol. 2004;20:781-810
references: 15473860
references: Oncogene. 2005 Feb 3;24(6):1098-103
references: 15592505
references: Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209-14
references: 17624989
references: Oncogene. 2006 Dec 4;25(57):7469-81
references: 17143291